Your session is about to expire
← Back to Search
Vasodilator
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
Phase 3
Waitlist Available
Research Sponsored by MediQuest Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Pivotal Trial
Summary
The purpose of this study is to determine if Vascana, a novel topical formulation of nitroglycerin, is effective in the treatment and prevention of the symptoms associated with Raynaud's Phenomenon.
Eligible Conditions
- Raynaud's Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: VascanaActive Control1 Intervention
Group II: VehiclePlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
MediQuest TherapeuticsLead Sponsor
10 Previous Clinical Trials
722 Total Patients Enrolled
Jeff Gregory, MDStudy DirectorMediQuest Therapeutics
3 Previous Clinical Trials
219 Total Patients Enrolled